Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 4, 2008, Pages 354-359

  Wilke, Russell A ^a   Berg, Richard L ^b   Linneman, James G ^b   Zhao, Chengfeng ^b   McCarty, Catherine A ^b   Krauss, Ronald M ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MARSHFIELD CLINIC   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; DATA BASE; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ALGORITHMS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DATABASES, GENETIC; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETICS, POPULATION; HEPTANOIC ACIDS; HUMANS; MALE; MEDICAL RECORDS; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PYRROLES; TREATMENT OUTCOME;

EID: 52049123312     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00291.x     Document Type: Article

References (28)

1. Family Study Committee for the Lipid Research Clinics Program. The Collaborative Lipid Research Clinics Program Family Study. I. Study design and description of data. Am J Epidemiol 1984 119 : 931 43.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 57.
3. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 295 : 1556 65.
4. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 291 : 1071 80.
5. Sever PS, Dahlof B, Pulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 : 1149 58.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 : 1301 7.
7. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997 80 : 106 7.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
9. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 360 : 1623 30.
10. Ridker PM, JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003 108 : 2292 7.
11. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003 2 : 517 26.
12. Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002 84 : 53 7.
13. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007 297 : 499 508.
14. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995 15 : 678 82.
15. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006 6 : 360 74.
16. McCarty CA, Wilke RA, Giampietro PF, Wesbrook SD, Caldwell MD. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Med 2005 2 : 49 79.
17. Kaiser J. Biobanks. Population databases boom, from Iceland to the USA. Science 2002 298 : 1158 61.
18. Davis RL, Khoury MJ. The journey to personalized medicine. Personalized Med 2005 2 : 1 4.
19. Sirohi E, Peissig P. Study of effect of drug lexicons on medication extraction from electronic medical records. Pac Symp Biocomput 2005 308 18.
20. Peissig P, Sirohi E, Berg RL, Brown-Switzer C, Ghebranious N, McCarty CA et al. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Basic Clin Pharmacol Toxicol 2007 100 : 286 8.
21. Greenlee RT. Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA). Clin Med Res 2003 1 : 273 80.
22. Davidian M, Gallant RA. The Nonlinear mixed effects model with a smooth random effects density. Biometrika 1993 80 : 475 88.
23. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford University Press, New York, 1994.
24. Wolfinger RD. Fitting Nonlinear Mixed Models with the New NLMIXED Procedure. Proceedings of the Twenty-fourth Annual SAS Users Group International Conference, SAS Institute Inc., Cary, NC, 1999.
25. Cilla DD, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996 36 : 604 9.
26. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
27. Wilke RA, Musana AK, Weber WW. Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice. Personalized Med 2005 2 : 213 24.
28. Wilke RA, Reif DG, Moore JH. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005 4 : 911 8.